Treatment of vasospastic angina.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000740:Anemia / Q000150:complications; D000788:Angina Pectoris, Variant / Q000150:complications / Q000188:drug therapy*; D001285:Atropine / Q000627:therapeutic use; D004110:Diltiazem / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000627:therapeutic use; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D006980:Hyperthyroidism / Q000150:complications; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D009756:Nylidrin / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D009599:Nitroprusside; D009756:Nylidrin; D001285:Atropine; D014700:Verapamil; D011464:Epoprostenol; D004110:Diltiazem; D005996:Nitroglycerin; D009543:Nifedipine; D007548:Isosorbide Dinitrate